Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions
2007
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Molecular mediators of hepatic steatosis and liver injury
2004 Standout
Thiazolidinediones
2004 Standout
Functional Bowel Disorders
2006 Standout
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
Changes in Hepatic Gene Expression upon Oral Administration of Taurine-Conjugated Ursodeoxycholic Acid in ob/ob Mice
2010
Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease
2008
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
1998
Liver fibrosis
2005 Standout
Nonalcoholic Fatty Liver Disease
2003
Mechanisms of liver fibrosis
2005
Nonalcoholic fatty liver disease
2002
The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease
2004
Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study
2001
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
2005 Standout
The metabolic syndrome
2010 Standout
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
2009
Nonalcoholic Fatty Liver Disease
2002 Standout
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
2001
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
2004 StandoutNobel
Steatohepatitis in children
2002
Drug-Induced Hepatotoxicity
2003 Standout
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
2010
Hepatic steatosis in obese patients: clinical aspects and prognostic significance
2004
Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease
2004
Silencing of Hepatic Fatty Acid Transporter Protein 5 in Vivo Reverses Diet-induced Non-alcoholic Fatty Liver Disease and Improves Hyperglycemia
2008
Bile acids and nonalcoholic fatty liver disease
2016
A Pilot Study of A Thiazolidinedione, Troglitazone, in Nonalcoholic Steatohepatitis
2001
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
2008 Standout
Apolipoprotein synthesis in nonalcoholic steatohepatitis
2002
Liver biopsy†
2008
Non-alcoholic fatty liver disease: The mist gradually clears
2008
Update on Nonalcoholic Fatty Liver Disease
2002
Non‐alcoholic fatty liver disease: An overview
2002
AGA technical review on nonalcoholic fatty liver disease
2002
Pharmacological agents for NASH
2013
Ultrasound-Guided Liver Biopsy for Parenchymal Liver Disease (An Economic Analysis)
1998
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects
2001
Inflammatory Bowel Disease
1991 Standout
Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates
2003
Cytokines and Nash: A Pilot Study of the Effects of Lifestyle Modification and Vitamin E
2003
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
2020
The metabolic syndrome
2005 Standout
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease
2001
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
2004
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Non-alcoholic fatty liver disease
2021 Standout
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
2005 Standout
Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
2005
An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities
2000
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
2010
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
2003 Standout
Prospective Evaluation of Unexplained Chronic Liver Transaminase Abnormalities in Asymptomatic and Symptomatic Patients
1999
Nonalcoholic Steatohepatitis in Children
2000
Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease
2005
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
2002 StandoutNobel
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
Cost-effectiveness of ultrasound-guided liver biopsy
1998
Beneficial Effects of Tumor Necrosis Factor-alpha Inhibition by Pentoxifylline on Clinical, Biochemical, and Metabolic Parameters of Patients with Nonalcoholic Steatohepatitis
2004
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis?
2001
Nonalcoholic steatohepatitis
2004
Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
1999 Standout
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
REVIEW: Nonalcoholic steatohepatitis
1997
Mechanisms for Insulin Resistance: Common Threads and Missing Links
2012 Standout
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis
2010
Nonalcoholic fatty liver disease
2005 Standout
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study
2001
Metformin in the treatment of patients with non‐alcoholic steatohepatitis
2004
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
2006 Standout
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey
2000
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
2010 Standout
Hepatocellular Carcinoma
2011 Standout
Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis
2006
Liver Biopsy
2001 Standout
Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study
2003
Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
2016
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies
2004
Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region?
2003
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
2005 Standout
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Evaluation of Liver Fibrosis: A Concise Review
2004
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
2007
Non‐alcoholic steatohepatitis in children and adolescents
2000
Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial
2004
Quality of Life in Patients on Permanent Home Parenteral Nutrition
1981
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
2004
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
2008
Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review
2009
Treatment of nonalcoholic fatty liver disease
2002
Ultrasound-Guided Biopsies of Abdominal Organs with an Automatic Biopsy System: A Retrospective Analysis of the Quality of Biopsies and of Hemorrhagic Complications
2000
Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
2000
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis
2003
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
2015
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Pharmacologic Treatment of the Irritable Bowel Syndrome
2000
A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease
2006
Nonalcoholic Steatohepatitis in Children
2000
A Critical Appraisal of the Quality of Quality-of-Life Measurements
1994 Standout
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus
2001
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
2011 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children
2000
Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in an Adult Population of Taiwan: Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese Adults
2006
Current best treatment for non-alcoholic fatty liver disease
2003
Molecular mediators of hepatic steatosis and liver injury
2004 Standout
Recent Developments in Nonspecific Inflammatory Bowel Disease
1982
Nonalcoholic Fatty Liver Disease
2015 Standout
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
2004 StandoutNobel
Works of D.B. McGill being referenced
Ursodeoxycholic Acid or Clofibrate in the Treatment of Non–Alcohol–Induced Steatohepatitis: A Pilot Study
1996
The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy
1996
Does Long‐Term Home Parenteral Nutrition in Adult Patients Cause Chronic Liver Disease?
1985
Home parenteral nutrition for management of the severely malnourished adult patient
1980
Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk
1983
Home Parenteral Nutrition as Primary Therapy in Patients with Extensive Crohn's Disease of the Small Bowel and Malnutrition
1977